Recent protocols15 have explored the development of blood‐based biomarkers (BBM) in the AT(N) framework, which has demonstrated promising diagnostic performance, and in addition have attempted to expand the initial framework to incorporate additional components, such as inflammatory markers (e.g., glial fibrillary acidic protein [GFAP]), to reflect the heterogeneity of AD better. This evidence concerns the gene GFAP and Alzheimer disease.